ISI provided color on Biogen Idec BIIB. In a research report published today, ISI is optimistic about the company's new drug, which has the potential of outperforming its competitors.
In the report, ISI states, “Abstracts for the ISTH meeting are out. For BIIB, the most important is the first description of phase I/II data for the company's long acting factor 8 program. The abstract says that the half-life is prolonged 66%-68% (depending on the assay) versus Baxter's Advate.”
On Tuesday, Biogen lost 1.31% of its value to finish the day at $104.05.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in